Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines.

Kröning, R., Katz, D., Lichtenstein, A. K., Nagami, G. T.

Defensins: antimicrobial and cytotoxic peptides of mammalian cells.

Lehrer, R. I., Lichtenstein, A. K., Ganz, T.

Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.

Vescio, R. A., Han, E. J., Schiller, G. J., Lee, J. C., Wu, C. H., Cao, J., Shin, J., Kim, A., Lichtenstein, A. K., Berenson, J. R.

Deletion of genetic material from a poly(ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies.

Cao, J., Hong, C. H., Rosen, L., Vescio, R. A., Smulson, M., Lichtenstein, A. K., Berenson, J. R.

Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines.

Kröning, R., Lichtenstein, A. K., Nagami, G. T.

Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma.

Yijiang Shi, Fumou Sun, Yan Cheng, Brent Holmes, Binod Dhakal, Joseph F Gera, Siegfried Janz, Alan Lichtenstein

Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation.

Mario Vega, Yu Chen, Yijiang Shi, Joseph Gera, Alan Lichtenstein

Function of Deptor and its roles in hematological malignancies.

Mario Morales-Martinez, Alan Lichtenstein, Mario I. Vega

Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.

Fumou Sun, Yan Cheng, Susan A. Walsh, Michael R. Acevedo, Xuefang Jing, Seong Su Han, Michael Pisano, Alan Lichtenstein, Fenghuang Zhan, Parameswaran Hari, Siegfried Janz, Michael H. Tomasson

Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma.

Angelica Benavides-Serrato, Jacquelyn T Saunders, Brent Holmes, Robert N. Nishimura, Alan Lichtenstein, Joseph Gera

A Deptor Inhibitor Induces Its Degradation with Resulting Anti-Myeloma Cytotoxicity in Vitro and In Vivo

Alan Lichtenstein

A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity.

Mario I. Vega, Yijiang Shi, Patrick Frost, Sara Huerta-Yepez, Gabriela Antonio-Andres, Rogelio Hernández-Pando, Jihye Lee, Michael E. Jung, Joseph Gera, Alan Lichtenstein

Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction.

Jihye Lee, Yijiang Shi, Mario I. Vega, Yonghui Yang, Joseph Gera, Michael E. Jung, Alan Lichtenstein

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.

Yijiang Shi, Tracy R. Daniels-Wells, Patrick Frost, Jihye Lee, Richard S. Finn, Carolyne Bardeleben, Manuel L. Penichet, Michael E. Jung, Joseph Gera, Alan Lichtenstein

Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.

Brent Holmes, Jihye Lee, Kenna A. Landon, Angelica Benavides-Serrato, Tariq Bashir, Michael E. Jung, Alan Lichtenstein, Joseph Gera

Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma

Alex Vasuthasawat, Esther M. Yoo, Kham R. Trinh, Alan Lichtenstein, John M. Timmerman, Sherie L. Morrison

SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism

Bao Hoang, Yijiang Shi, Patrick Frost, Veena Mysore, Carolyne Bardeleben, Alan Lichtenstein

Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress

Yijiang Shi, Yonghui Yang, Bao Hoang, Carolyne Bardeleben, Brent Holmes, Joseph Gera, Alan Lichtenstein

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.

, , , , , , , , , , , , , , , , ,

Anti-CD138-Targeted Interferon Is a Potent Therapeutic Against Multiple Myeloma

Esther M. Yoo, Kham R. Trinh, Danh Tran, Alex Vasuthasawat, Juan Zhang, Bao Hoang, Alan Lichtenstein, Sherie L. Morrison

DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells

Yonghui Yang, Carolyne Bardeleben, Patrick Frost, Bao Hoang, Yijiang Shi, Richard A Finn, Joseph Gera, Alan Lichtenstein

MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses.

Yijiang Shi, Patrick Frost, Bao Hoang, Yonghui Yang, Carolyne Bardeleben, Joseph Gera, Alan Lichtenstein

Anemia in lymphoma: interleukin-6, hepcidin and erythropoietin

Alan Lichtenstein

Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells

Carolyne Bardeleben, Sanjai Sharma, Joseph R. Reeve, Sara Bassilian, Patrick Frost, Bao Hoang, Yijiang Shi, Alan Lichtenstein

Mammalian Target of Rapamycin Inhibitors Induce Tumor Cell Apoptosis In Vivo Primarily by Inhibiting VEGF Expression and Angiogenesis

Patrick Frost, Eileen Berlanger, Veena Mysore, Bao Hoang, Yijiang Shi, Joseph Gera, Alan Lichtenstein

MNK KINASES FACILITATE C-MYC IRES ACTIVITY IN RAPAMYCIN-TREATED MULTIPLE MYELOMA CELLS

Yijiang Shi, Patrick Frost, Bao Hoang, Yonghui Yang, Rikiro Fukunaga, Joseph Gera, Alan Lichtenstein

Iron in Multiple Myeloma

Tracy R. Daniels-Wells, Manuel L. Penichet, Alan Lichtenstein, Kristina VanderWall

The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance

Bao Hoang, Angelica Benavides, Yijiang Shi, Yonghui Yang, Patrick Frost, Joseph Gera, Alan Lichtenstein

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.

Joseph Gera, Alan Lichtenstein

Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma

Cheri Cloninger, Andrew Bernath, Tariq Bashir, Brent Holmes, Nicholas Artinian, Teresa Ruegg, Lauren Anderson, Janine Masri, Alan Lichtenstein, Joseph Gera

Exon 11 skipping of E-cadherin RNA downregulates its expression in Head and Neck cancer cells

Sanjai Sharma, Wei Liao, Xiaofeng Zhou, David T.W. Wong, Alan Lichtenstein

Phosphomimetic Substitution of Heterogeneous Nuclear Ribonucleoprotein A1 at Serine 199 Abolishes AKT-dependent Internal Ribosome Entry Site-transacting Factor (ITAF) Function via Effects on Strand Annealing and Results in Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitor Sensitivity

Jheralyn Martin, Janine Masri, Cheri Cloninger, Brent Holmes, Nicholas Artinian, Alexander Funk, Teresa Ruegg, Lauren Anderson, Tariq Bashir, Andrew Bernath, Alan Lichtenstein, Joseph Gera

IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells CRITICAL ROLE OF CYTOPLASMIC LOCALIZATION OF THE RNA-BINDING PROTEIN hnRNP A1

Yijiang Shi, Patrick Frost, Bao Hoang, Angelica Benavides, Joseph Gera, Alan Lichtenstein

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

Bao Hoang, Patrick Frost, Yijiang Shi, Eileen Belanger, Angelica Benavides, Gholam Pezeshkpour, Susanna Cappia, Tommasina Guglielmelli, Joseph Gera, Alan Lichtenstein

In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2

Ken Maes, Elizabeta Nemeth, Alissa Huston, Flavia Esteve, Cesar O. Freytes, Natalie S. Callander, Eirini Katodritou, Lisa Tussing-Humphreys, Seth Rivera, Karin Vanderkerken, Alan Lichtenstein, Tomas Ganz, G. David Roodman

Effect of autophagy on multiple myeloma cell viability.

Bao Hoang, Angelica Benavides, Yijiang Shi, Patrick Frost, Alan Lichtenstein

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal–regulated kinase inhibitors and rapamycin

Patrick Frost, Yijiang Shi, Bao Hoang, Joseph Gera, Alan Lichtenstein

IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.

Yijiang Shi, Patrick Frost, Bao Q. Hoang, Angelica Benavides, Sanjai Sharma, Joseph Gera, Alan Lichtenstein

Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells

Sanjai Sharma, Alan Lichtenstein

Heterogeneous Nuclear Ribonucleoprotein A1 Regulates Cyclin D1 and c-myc Internal Ribosome Entry Site Function through Akt Signaling

Oak D. Jo, Jheralyn Martin, Andrew Bernath, Janine Masri, Alan Lichtenstein, Joseph Gera

Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors

Sanjai Sharma, Alan Lichtenstein

Analysis of multiple myeloma third complementarity-determining regions reveals characteristics of prenatal B cells.

L. A. Kunkel, Robert Vescio, J. Cao, C. H. Hong, A. Kim, Gary J. Schiller, Alan Lichtenstein, James R. Berenson

Involvement of Hepcidin in the Anemia of Multiple Myeloma

Sanjai Sharma, Elizabeta Nemeth, Yi Hsiang Chen, Julia B. Goodnough, Alissa Huston, Tomas Ganz, Alan Lichtenstein, G. D. Roodman

Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies

Maryla Krajewska, Shinichi Kitada, Jane N. Winter, Daina Variakojis, Alan Lichtenstein, Dayong Zhai, Michael Cuddy, Xianshu Huang, Frederic Luciano, Cheryl H. Baker, Hoguen Kim, Eunah Shin, Susan Kennedy, Allen Olson, Andrzej Badzio, Jacek Jassem, I. Meinhold-Heerlein, MichaelJ. Duffy, Aaron D. Schimmer, Ming Tsao, Ewan Brown, Anne Sawyers, Michael Andreeff, Dan Mercola, Stan Krajewski, John C. Reed

Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma

Frederic Luciano, Maryla Krajewska, Paulina Ortiz-Rubio, Stan Krajewski, Dayong Zhai, Benjamin Faustin, Jean-Marie Bruey, Béatrice Bailly-Maitre, Alan Lichtenstein, Siva Kumar Kolluri, Arnold C. Satterthwait, Xiao-kun Zhang, John C. Reed

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

Patrick Frost, Yijiang Shi, Bao Hoang, Alan Lichtenstein

Targeting aurora kinases as therapy in multiple myeloma

Yijiang Shi, Tony Reiman, Weiqun Li, Christopher A. Maxwell, Subrata Sen, Linda M. Pilarski, Tracy R. Daniels, Manuel L. Penichet, Rick Feldman, Alan Lichtenstein

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

Bao Hoang, Li Zhu, Yijiang Shi, Patrick Frost, Huajun Yan, Sanjai Sharma, Sherven Sharma, Lee Goodglick, Steven M. Dubinett, Alan Lichtenstein

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.

Huajun Yan, Patrick Frost, Yijiang Shi, Bao Hoang, Sanjai Sharma, Myrna Fisher, Joseph Gera, Alan Lichtenstein

Cyclooxygenase-2-Dependent Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-6 in Non–Small Cell Lung Cancer

Harnisha Dalwadi, Kostyantyn Krysan, Nathalie Heuzé-Vourc'h, Mariam Dohadwala, David Elashoff, Sherven Sharma, Nicholas A. Cacalano, Alan Lichtenstein, Steven M. Dubinett

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade

Yijiang Shi, Huajun Yan, Patrick Frost, Joseph Gera, Alan Lichtenstein

Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.

Yijiang Shi, Anushree Sharma, Hong Wu, Alan Lichtenstein, Joseph Gera

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

Patrick Frost, Farhad Moatamed, Bao Hoang, Yijiang Shi, Joseph Gera, Huajun Yan, Philip Frost, Jay Gibbons, Alan Lichtenstein

Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

Jung-hsin Hsu, Yijiang Shi, Patrick Frost, Huajun Yan, Bao Hoang, Sanjai Sharma, Joseph Gera, Alan Lichtenstein

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Joseph Gera, Ingo K. Mellinghoff, Yijiang Shi, Matthew Rettig, Chris Tran, Jung-hsin Hsu, Charles L. Sawyers, Alan Lichtenstein

Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway

Jie Zhang, Yong Choi, Blanche Mavromatis, Alan Lichtenstein, Weiqun Li

Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells

Yijiang Shi, Joseph Gera, Jung hsin Hsu, Brian G Van Ness, Alan Lichtenstein

Downstream effectors of oncogenic ras in multiple myeloma cells

Liping Hu, Yijiang Shi, Jung hsin Hsu, Joseph Gera, Brian G Van Ness, Alan Lichtenstein

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Elizabeta Nemeth, Erika V. Valore, Mary C. Territo, Gary J. Schiller, Alan Lichtenstein, Tomas Ganz

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

Yijiang Shi, Joseph Gera, Liping Hu, Jung-hsin Hsu, Robert Bookstein, Weiqun Li, Alan Lichtenstein

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

Yijiang Shi, Jung-hsin Hsu, Liping Hu, Joseph Gera, Alan Lichtenstein

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses

Jung-hsin Hsu, Yijiang Shi, Liping Hu, Myrna Fisher, Thomas F. Franke, Alan Lichtenstein

The Kaposi sarcoma–associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element

Jiabin An, Alan Lichtenstein, Gregory A. Brent, Matthew Rettig

The AKT kinase is activated in multiple myeloma tumor cells.

Jung-hsin Hsu, Yijiang Shi, Stanislaw Krajewski, Stephen W. Renner, Myrna Fisher, John C. Reed, Thomas F. Franke, Alan Lichtenstein

Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer.

Min Huang, Raj K. Batra, Takahiko Kogai, Ying Q. Lin, Jerome M. Hershman, Alan Lichtenstein, Sherven Sharma, Li X. Zhu, Gregory A. Brent, Steven M. Dubinett

The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.

Yiping Tu, Agnes Gardner, Alan Lichtenstein

Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism.

Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananév V, Bazin I, Garin A, Narimanov M, Knysh V, Melkonyan H, Umansky S, Lichtenstein A

Expression of BAX in Plasma Cell Dyscrasias

Stephen W. Renner, Jeffrey Weisz, Stanislaw Krajewski, Maryla Krajewska, John C. Reed, Alan Lichtenstein

Interleukin-6–Induced Inhibition of Multiple Myeloma Cell Apoptosis: Support for the Hypothesis That Protection Is Mediated Via Inhibition of the JNK/SAPK Pathway

Feng-hao Xu, Sanjesh Sharma, Agnes Gardner, Yiping Tu, Arthur Raitano, Charles Sawyers, Alan Lichtenstein

Taxol can induce phosphorylation of BCL-2 in multiple myeloma cells and potentiate dexamethasone-induced apoptosis.

Relef Kroning, Alan Lichtenstein

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

James R. Berenson, Alan Lichtenstein, Lester Porter, Meletios A. Dimopoulos, Roldolfo Bordoni, Sebastian George, Alan Lipton, Alan Keller, O. F. Ballester, Michael J. Kovacs, Hillary Blacklock, Richard Bryan Bell, Joseph F. Simeone, Dirk J. Reitsma, Maika Heffernan, John J. Seaman, Rob Knight

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

Ana Aparicio, A. Gardner, Yiping Tu, A. Savage, J. Berenson, Alan Lichtenstein

BCL-X expression in multiple myeloma: possible indicator of chemoresistance.

Yiping Tu, Steven Renner, Feng-hao Xu, Alex Fleishman, Jeremy M. G. Taylor, Jeffrey Weisz, Robert Vescio, Matthew Rettig, James R. Berenson, Stanislaw Krajewski, John C. Reed, Alan Lichtenstein

Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.

Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu CH, Cao J, Lee JC, Lichtenstein A, Lill M, Berenson R, Berenson J

Inhibition of Lymphocyte Function by Head and Neck Carcinoma Cell Line Soluble Factors

Jeffrey W. Bailet, Alan Lichtenstein, Ge Chen, Robert A. Mickel

Evidence against the hypothesis that BCL-2 inhibits apoptosis through an anti-oxidant effect.

Agnes Gardner, Feng-hao Xu, Catherine Fady, Theodore A. Sarafian, Yiping Tu, Alan Lichtenstein

Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors

Feng-hao Xu, Agnes Gardner, Yiping Tu, Patrick Michl, Diane Prager, Alan Lichtenstein

Suppressive Factor or Factors Derived from Head and Neck Squamous Cell Carcinoma Induce Apoptosis in Activated Lymphocytes

Kathleen R. Billings, Marilene B. Wang, Alan Lichtenstein

Apoptotic vs. Nonapoptotic Cytotoxicity Induced by Hydrogen Peroxide

Agnes Gardner, Feng-hao Xu, Catherine Fady, Fred J. Jacoby, Dianne C. Duffey, Yiping Tu, Alan Lichtenstein

Upregulated Expression of BCL-2 in Multiple Myeloma Cells Induced by Exposure to Doxorubicin, Etoposide, and Hydrogen Peroxide

Yiping Tu, Feng-hao Xu, Jin Liu, Robert Vescio, James Berenson, Catherine Fady, Alan Lichtenstein

Regulation of Transforming Growth Factor-β1-Mediated Apoptosis in Head and Neck Squamous Cell Carcinoma

Dianne C. Duffey, Thomas C. Calcaterra, Alan Lichtenstein

Terminal transferase expression in the differential diagnosis of acute leukemias. Eastern Cooperative Oncology Group.

Meenan B, Heavey C, Lichtenstein A, Andersen J, Paietta E

Apoptotic Inhibition of Head and Neck Squamous Cell Carcinoma Cells by Tumor Necrosis Factor α

Kenneth B. Briskin, Catherine Fady, Marilene B. Wang, Alan Lichtenstein

VH gene usage is multiple myeloma: complete absence of the VH4.21 (VH4-34) gene.

Matthew Rettig, Robert Vescio, Jin Cao, C. H. Wu, Jong C. Lee, Eugene Han, Melina DerDanielian, Roland Newman, Charlie Hong, Alan Lichtenstein, James R. Berenson

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

James R. Berenson, Alan Lichtenstein, Lester Porter, Meletios A. Dimopoulos, Roldolfo Bordoni, Sebastian George, Allan Lipton, Alan Keller, O. F. Ballester, Michael J. Kovacs, Hilary A. Blacklock, Richard Bell, Joseph F. Simeone, Dirk J. Reitsma, Maika Heffernan, John J. Seaman, Robert Knight

A CD10-positive subset of malignant cells is identified in multiple myeloma using PCR with patient-specific immunoglobulin gene primers.

Cao J, Robert Vescio, Matthew Rettig, C. H. Hong, A. Kim, J. C. Lee, Alan Lichtenstein, Berenson

Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity.

R. A. Vescio, Jin Cao, C. H. Hong, J. C. Lee, C. H. Wu, M. Der Danielian, V. Wu, R. Newman, Alan Lichtenstein, James R. Berenson

Inhibition of head and neck squamous cell carcinoma cell lines by transforming growth factor-β

Kenneth B. Briskin, Catherine Fady, Robert A. Mickel, Marilene B. Wang, Alan Lichtenstein

Interleukin-6 inhibits apoptosis of malignant plasma cells.

Alan Lichtenstein, Yiping Tu, Catherine Fady, Robert Vescio, James R. Berenson

Identification of malignant cells in multiple myeloma bone marrow with immunoglobulin VH gene probes by fluorescent in situ hybridization and flow cytometry.

Jin Cao, R. A. Vescio, C. H. Hong, A. Kim, Alan Lichtenstein, J. B. Berenson

Atypical apoptotic cell death induced in L929 targets by exposure to tumor necrosis factor

Catherine Fady, Agnes Gardner, Freddie Jacoby, Kenneth B. Briskin, Yiping Tu, Ingrid Schmid, Alan Lichtenstein

Multiple myeloma clones are derived from a cell late in B lymphoid development.

James R. Berenson, Robert Vescio, C. H. Hong, Jin Cao, A. Kim, C. C. Lee, Gary J. Schiller, R. J. Berenson, Alan Lichtenstein

The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma

Robert A. Vescio, Charlie H. Hong, Jin Cao, Austin Kim, Gary J. Schiller, Alan Lichtenstein, Ronald J. Berenson, James R. Berenson

Expression of shared idiotypes by paraproteins from patients with monoclonal gammopathy of undetermined significance.

Carsten E. Kampe, Sarah Hart, Richard A. Miller, Alan Lichtenstein, Robert A. Kyle, James R. Berenson

Tumor Necrosis Factor-α Plays a Central Role in Interleukin-2-Induced Pulmonary Vascular Leak and Lymphocyte Accumulation

Steven M. Dubinett, Min Huang, Alan Lichtenstein, William H. McBride, Jianyi Wang, Gerald Markovitz, David Kelley, Wayne W. Grody, Leah E. Mintz, Shawkat Dhanani

Corticotropin-Releasing Factor Reduces Lipopolysaccharide-Induced Pulmonary Vascular Leak

David M. Kelley, Alan Lichtenstein, Jianyi Wang, Anna N. Taylor, Steven M. Dubinett

A polymerase chain reaction-based microsatellite typing assay used for tumor cell line identification.

King BL, Lichtenstein A, Berenson J, Kacinski BM

Inhibition of DNA repair with aphidicolin enhances sensitivity of targets to tumor necrosis factor.

Joseph Gera, Catherine Fady, Agnes Gardner, F J Jacoby, K B Briskin, Alan Lichtenstein

Interferon-γ-induced increased sensitivity of HER2/neu -overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events

Catherine Fady, Agnes Gardner, Joseph Gera, Alan Lichtenstein

Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events

Catherine Fady, Agnes Gardner, Joseph Gera, Alan Lichtenstein

A duplicated region is responsible for the poly(ADP-ribose) polymerase polymorphism, on chromosome 13, associated with a predisposition to cancer.

Lyn D, Cherney BW, Lalande M, Berenson JR, Lichtenstein A, Lupold S, Bhatia KG, Smulson M

Effects of β-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis

Alan Lichtenstein, Catherine Fady, Joseph Gera, Agnes Gardner, Victoria R. Chazin, David Kelley, James R. Berenson

Interferon-induced Increase in Sensitivity of Ovarian Cancer Targets to Lysis by Lymphokine-activated Killer Cells: Selective Effects on HER2/neu-overexpressing Cells

Catherine Fady, Agnes Gardner, Joseph Gera, Alan Lichtenstein

Human neutrophil peptide defensins induce single strand DNA breaks in target cells

Joseph Gera, Alan Lichtenstein

Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma.

Marilene B. Wang, Alan Lichtenstein, Robert A. Mickel

Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane.

Lichtenstein A

Inhibitors of ADP-ribose polymerase decrease the resistance of HER2/neu-expressing cancer cells to the cytotoxic effects of tumor necrosis factor.

Alan Lichtenstein, Joseph Gera, J S Andrews, James R. Berenson, Carl F. Ware

Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.

Alan Lichtenstein, James R. Berenson, Joseph Gera, Kristine Waldburger, Otoniel Martinez-Maza, Jonathan S. Berek

Oncogenes in multiple myeloma: point mutation of N-ras.

Paquette RL, Berenson J, Lichtenstein A, McCormick F, Koeffler HP

First place--Resident Clinical Science Award 1990. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck.

Barry Strasnick, Nestor Lagos, Alan Lichtenstein, Robert A. Mickel

Expression of shared idiotypes by paraproteins from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

James R. Berenson, Alan Lichtenstein, Sarah Hart, David Palomares, Richard A. Miller

Direct Cytotoxicity of Polymorphonuclear Leukocyte Granule Proteins to Human Lung-derived Cells and Endothelial Cells

Derek G. Okrent, Alan Lichtenstein, Tomas Ganz

Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.

Fred R. Leess, James K. Bredenkamp, Alan Lichtenstein, Robert A. Mickel

Clonal rearrangement of immunoglobulin genes in the peripheral blood of multiple myeloma patients.

James R. Berenson, Alan Lichtenstein, Bernard Klein, Régis Bataille

Production of cytokines by bone marrow cells obtained from patients with multiple myeloma

Alan Lichtenstein, James Berenson, D C Norman, Mei-Ping Chang, Anne Carlile

Human neutrophil-mediated lysis of ovarian cancer cells

Alan Lichtenstein, Miriam Seelig, Jonathan S. Berek, Jacob Zighelboim

Inadvertent passage of a pulmonary artery catheter from the superior vena cava through the left atrium and left ventricle into the aorta.

John W. Allyn, Alan Lichtenstein, E. Greg Koski, Marshall L. Jacobs, Edward Lowenstein

Clonal rearrangement of the beta-T cell receptor gene in multiple myeloma.

Berenson J, Lichtenstein A

Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.

Alan Lichtenstein, Celsa A. Spina, Jonathan S. Berek, Tyler Jung, Jacob Zighelboim

Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients.

Robert A. Mickel, David J. Kessler, Jeremy M. G. Taylor, Alan Lichtenstein

Unplanned intraoperative and postoperative hemodilution: oxygen transport and consumption during severe anemia.

Alan Lichtenstein, Will F. Eckhart, Karen J. Swanson, Charles A. Vacanti, Warren M. Zapol

Synergistic cytolysis mediated by hydrogen peroxide combined with peptide defensins

Alan Lichtenstein, Tomas Ganz, Michael E. Selsted, Robert I. Lehrer

Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity.

Alan Lichtenstein, Tomas Ganz, The-Minh Nguyen, Michael E. Selsted, Robert I. Lehrer

Depressed Natural Killer Cell Activity in Cervical Lymph Nodes Containing Focal Metastatic Squamous Cell Carcinoma

David J. Kessler, Robert A. Mickel, Alan Lichtenstein

Neutrophil-mediated nonoxidative tumor lysis stimulated by high concentrations of phorbol myristate acetate.

Alan Lichtenstein

Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma.

James R. Berenson, Rex Wong, Kenneth Kim, Nathaniel A. Brown, Alan Lichtenstein

Stimulation of the respiratory burst of murine peritoneal inflammatory neutrophils by conjugation with tumor cells.

Alan Lichtenstein

Antigen-specific suppression of the in vitro cytotoxic response by a soluble factor produced by corynebacterium parvum-induced allospecific suppressor cells☆

Marilou Terpenning, Alan Lichtenstein, Jacob Zighelboim

Antitumor effect of the streptococcal preparation OK-432 in a murine model of ovarian cancer.

Alan Lichtenstein

In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes.

Alan Lichtenstein, Tomas Ganz, Michael E. Selsted, Robert I. Lehrer

Spontaneous tumor cytolysis mediated by inflammatory neutrophils: dependence upon divalent cations and reduced oxygen intermediates

Alan Lichtenstein

Enhancement of Natural Killer Cytotoxicity by cis-Diamminedichloroplatinum (II) in Vivo and in Vitro

Alan Lichtenstein, Daniela Pende

Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes.

Alan Lichtenstein, Jonathan S. Berek

Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.

Jonathan S. Berek, Neville F. Hacker, Alan Lichtenstein, T. Jung, Celsa A. Spina, Reba M. Knox, Brady J, Greene T, Ettinger Lm, Leo D. Lagasse

Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model.

Jonathan S. Berek, Alan Lichtenstein, Reba M. Knox, Tyler Jung, Thanne P. Rose, John L. Cantrell, Jacob Zighelboim

Rejection of murine ovarian cancer following treatment with regional immunotherapy: correlations with a neutrophil-mediated activation of cytostatic macrophages

Alan Lichtenstein

Intraperitoneal Recombinant α-Interferon for “Salvage” Immunotherapy in Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Jonathan S. Berek, Neville F. Hacker, Alan Lichtenstein, Tyler Jung, Celsa A. Spina, Reba M. Knox, Jeanine Brady, Teri Greene, Lupe M. Ettinger, Leo D. Lagasse, Eric M. Bonnem, Robert J. Spiegel, Jacob Zighelboim

Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum.

Jonathan S. Berek, Robert C. Knapp, Neville F. Hacker, Alan Lichtenstein, Tyler Jung, Celsa A. Spina, R. Obrist, C. Thomas Griffiths, Ross S. Berkowitz, Leroy M. Parker, Jacob Zighelboim, Robert C. Bast

Use of a self-generating percoll gradient and single cell cytotoxicity assay to identify tumor-lytic properties of inflammatory neutrophils

Alan Lichtenstein, Janet Kahle, Benjamin Bonavida

Natural Killer Inhibitory Substance Produced by the Peritoneal Cells of Patients With Ovarian Cancer

Alan Lichtenstein, Jonathan S. Berek, Jacob Zighelboim

Anti-tumor effect of inflammatory neutrophils: characteristics of in vivo generation and in vitro tumor cell lysis.

Alan Lichtenstein, Janet Kahle

Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.

Alan Lichtenstein, Jonathan S. Berek, Janet Kahle, Jacob Zighelboim

Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.

Jonathan S. Berek, Robert C. Bast, Alan Lichtenstein, Neville F. Hacker, Celsa A. Spina, Leo D. Lagasse, Robert C. Knapp, Jacob Zighelboim

Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.

Alan Lichtenstein, J Kahle, Jonathan S. Berek, Jacob Zighelboim

Immunotherapy with Biochemically Dissociated Fractions of Propionibacterium acnes in a Murine Ovarian Cancer Model

Jonathan S. Berek, John L. Cantrell, Alan Lichtenstein, Neville F. Hacker, Reba M. Knox, Roberta K. Nieberg, Thanne Poth, Robert Elashoff, Leo D. Lagasse, Jacob Zighelboim

Peripheral blood lymphocytes with receptors for a determinant common to B-lymphoblastoid cell lines and acute myelogenous leukemia blasts.

Alan Lichtenstein, Faramarz Naiem, Jacob Zighelboim

Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.

Alan Lichtenstein, Jonathan S. Berek, Robert C. Bast, Celsa A. Spina, Neville F. Hacker, Robert C. Knapp, Jacob Zighelboim

Inhibition of natural killer cell lysis by natural killer-inhibitory substance: mechanism of suppression.

Alan Lichtenstein, Robert Mickel, Jacob Zighelboim

Regulation of cytotoxic reactivity to minor histocompatibility antigens by administration of Corynebacterium parvum.

Alan Lichtenstein, Melané Ali, Philip Mack, Jacob Zighelboim

Inhibition of Natural Killer Cell Activity by a Soluble Substance Released by Rat Peritoneal Cells

Jacob Zighelboim, Alan Lichtenstein, Aron Bick, Robert A. Mickel

Augmentation of NK activity by Corynebacterium parvum fractions in vivo and in vitro

Alan Lichtenstein, Aron Bick, John L. Cantrell, Jacob Zighelboim

Effects of different fractions of corynebacterium parvum on the cytotoxic t-cell response to alloantigens in mice.

Alan Lichtenstein, Richard L. Tuttle, John L. Cantrell, Jacob Zighelboim

Activation and mechanism of action of suppressor macrophages

Alan Lichtenstein, Richard I. Murahata, Marilou Terpenning, John L. Cantrell, Jacob Zighelboim

Immunoblastic sarcoma of T-cell versus B-cell origin: I. Clinical features

Alexandra M. Levine, Clive R. Taylor, Schneider, SC Koehler, Stephen J. Forman, Alan Lichtenstein, Robert J. Lukes, Donald I. Feinstein

Response of normal subjects to mitogens. I. Influence of adherent cells.

Zighelboim J, Lichtenstein A, Benjamin D

Suppressor T cells and suppressor macrophages induced by Corynebacterium parvum.

Alan Lichtenstein, Richard I. Murahata, Roy I. Sugasawara, Jacob Zighelboim

Peripheral blood lymphocyte receptors for B-lymphoblastoid cell lines (B-LCL)

Jacob Zighelboim, Alan Lichtenstein

Clinical and immunologic spectrum of plasmacytoid lymphocytic lymphoma without serum monoclonal IgM.

Alexandra M. Levine, Alan Lichtenstein, Mary V. Gresik, Clive R. Taylor, Donald I. Feinstein, Robert J. Lukes

Serum immunoglobulin levels in patients with non-Hodgkin's lymphoma.

Alan Lichtenstein, Clive R. Taylor

Comparison of immune derangements in patients with different malignancies.

Lichtenstein A, Zighelboim J, Dorey F, Brossman S, Fahey JL

Primary mediastinal lymphoma in adults

Alan Lichtenstein, Alexandra M. Levine, Clive R. Taylor, William D. Boswell, Stanley Rossman, Donald I. Feinstein, Robert J. Lukes

Immunoblastic sarcoma: a clinical description.

Alan Lichtenstein, Alexandra M. Levine, Robert J. Lukes, Adelbert D. Cramer, Clive R. Taylor, Thomas L. Lincoln, Donald I. Feinstein